Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — Investor Presentation (August 2021)
19 slides from Catheter Precision's investor presentation, Aug 24, 2021
Slide 1: Corporate Presentation August 2021
Ra Medical Systems, Inc. NYSE American: RMED Corporate Presentation August 2021 1 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems, Inc. (the “Company”) and involve known and unknown risks, uncertainties and othe
Slide 3: Opportunity: Focus on Engineering & Clinical Execution
Opportunity Focus on Engineering & Clinical Execution Engineering efforts focused on development of next-generation DABRA catheters with expected FDA submissions in 2022 U.S. clinical study underway to obtain an atherectomy indication with an expected FDA submission in 2022 Promising early research
Slide 4: DABRA Targets Large PAD Market
DABRA Targets Large PAD Market 2 The Sage Group 2014 3 Millennium Research Group December 2020 4 FDA-approved atherectomy indication study enrolling in US 1 The Sage Group 2021
Slide 5: DABRA Strategy
DABRA Strategy Engineering focus is programs to enhance DABRA catheter deliverability with next-gen catheter products Clinical focus is execution of an FDA-approved clinical study to obtain an atherectomy indication Early research demonstrates the potential to perform intravascular lithotripsy in ca
Slide 6: DABRA Catheter Engineering Programs
DABRA Catheter Engineering Programs Extend shelf life of DABRA catheters Root causes of shelf-life limitations identified in 2020 Mitigation plans are being implemented with in-house accelerated & real-time aging data supporting 6-month shelf life for future generation catheters Next-gen DABRA cathe
Slide 7: Intravascular Lithotripsy Research Project
Intravascular Lithotripsy Research Project Purpose Demonstrate feasibility of performing lithotripsy with an excimer laser-based system Progress to date Pressure measurements demonstrate peak shockwave pressures that exceed 50 atmospheres of peak pressure Successful in shattering medial calcium mode
Slide 8: DABRA Clinical Study for Initial FDA Clearance
DABRA Clinical Study for Initial FDA Clearance DABRA effectiveness as measured by successful crossing of target lesion 94% The pivotal study formed the basis of our May 24, 2017 510(k) clearance. For information on how we defined device-related SAEs for purposes of our pivotal study, see https://cli
Slide 9: FDA-Approved IDE Atherectomy Indication Study
FDA-Approved IDE Atherectomy Indication Study Primary safety endpoint: The incidence of 30-day Major Adverse Events (MAEs) as adjudicated by the Clinical Events Committee: All-cause mortality Unplanned major target limb amputation (at or above the ankle) and/or Clinically driven target limb revascul
Slide 10: Intellectual Property Portfolio
Intellectual Property Portfolio Patents covering several aspects of the laser systems and delivery device The Company believes that its intellectual property comprises novel and useful inventions that can be protected by patents, and as such, has filed patent applications directed to innovative meth
Slide 11: Results of Operations
Results of Operations * Adjusted EBITDA is a non-GAAP measure and is calculated as net profit (loss) excluding interest income (expense), income tax expense and certain recurring, non-cash charges such as depreciation and amortization of long-lived assets as well as stock-based compensation expenses
Slide 12: Financial Position
Financial Position We received approx. $4.4 million in July and August 2021 under our at the market offering program We define working capital as current assets minus current liabilities Fully repaid in March 2021 Fully forgiven in June 2021 Cash management remains a priority
Slide 13: Recent & Future Milestones
Recent & Future Milestones *Unable to accurately predict atherectomy indication study enrollment due to COVID-19 impact
Slide 14: Turnaround Opportunity With Focus On Execution
Turnaround Opportunity With Focus On Execution Focus on Engineering & Clinical Execution DABRA is an excimer laser and single-use catheter system used in the endovascular treatment of vascular blockages resulting from PAD Engineering efforts focused on development of next-generation DABRA catheters
Slide 15: Appendix
Appendix
Slide 16: R&D and Manufacturing Facility
R&D and Manufacturing Facility Carlsbad, CA 41,000 sq. ft. in Carlsbad, CA with three controlled environments Sizable capacity for laser and catheter production Fully capitalized with all equipment owned ISO13485 certified, FDA and CA state inspected Laser Assembly Controlled Environments
Slide 17: Management Team
Management Team Will McGuire Corporaon, Coven and Glan Corporation, Most recent CEO of uty ttaded Second Sight Medical Products. Mi ‘Meaial). MBA and CPA (active) ‘Al Memmoto Quality, Clinical and including Chief Operating Offer at Dalen Medical and Vice President at MBA Chris Folk, PhD ‘and PhD, Ae
Slide 18: Board of Directors
Board of Directors Martin Colombatto Chairman Former VP and General Manager of Broadcom William Enquist Former Presider of Stryker Will McGuire Chief Executive Oficer, Ra Mecical Richard Mejia Former Partner of Est & Young Susanne Meline Co-founder of Francis Capital Management Joan Stafslien Former
Slide 19: Reconciliation of Net loss to Adjusted EBITDA
Reconciliation of Net loss to Adjusted EBITDA
Ra Medical Systems — Investor Presentation (August 2021) on 6ix